Loading…

P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study

Saved in:

Bibliographic Details
Published in:	Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2023-09, Vol.23, p.S52-S53
Main Authors:	Costa, Luciano, Bar, Noffar, Mateos, Maria-Victoria, Ribas, Paz, Hansson, Markus, Paris, Laura, Hofmeister, Craig, Rodriguez-Otero, Paula, Bermúdez, Maria Aranzazu, Santoro, Armando, Yee, Andrew, Creignou, Maria, Encinas, Cristina, Cerchione, Claudio, de la Rubia, Javier, Oriol, Albert, Ferstl, Barbara, Besemer, Britta, Chen, Jinjie, Boss, Isaac, Gaudy, Allison, Hsu, Kevin, Godwin, Colin, San-Miguel, Jesús, Wong, Sandy
Format:	Article
Language:	English
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!